Dee Mcleod, M.D.

Board Certified Medical Oncologist dedicated to providing comprehensive medical care and ensuring patient well-being. Experienced across diverse healthcare settings, including hospitals, community clinics, insurance companies, and government agencies. Seeking a Locum Tenens position to leverage extensive experience. Demonstrated expertise in accurate diagnosis and effective treatment of various medical conditions. Committed to delivering high-quality healthcare services and improving patient outcomes.

Texas (active)

New York ( active)

NHL-008" A Randomized Phase IIb Study of Lenalidomide Plus Rituximab Followed By Lenalidomide Single Agent Maintenance vs. Rituximab Maintenance In Subjects with Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma"- Sub Investigator

NSABP-B49 " A Phase III Clinical Trial Comparing The Combination of Docetaxel Plus Cyclophosphamide  to Anthracycline- Basec Chemotherapy Regimens  for WNODE NEGATIVE, HER2 NEGATIVE BREAST CANCER"- PRINCIPAL INVESTIGATOR

P10-3" A REGISTRY OF SIPULRUCRL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER ( PROCEED) "- PRINCIPAL INVESTIGATOR

CALGB 70305" A RANDOMIZED STUDY TO PREVENT LYMPHEDEMA IN WOMEN TREATED FOR BREAST CANCER WITH STAGE I-III BREAST CANCER AND SENTINEL OR AXILLARY NODE DISSECTION" - SUB-INVESTIGATOR

SWOG- S1007 " A PHASE III RANDOMIZED CLINICAL TRIAL OF STANDARD ADJUVANT ENDOCRINE THERAPY +/- CHEMOTHERAPY IN PATIENTS WITH 1-3 POSITIVE NODES, HORMONE RECEPTOR -POSITIVE AND HER2NEGATIVE BREAST CANCER WITH RECURRENCE SCORE OF 25 OR LESS" - SUB-INVESTIGATOR

• Board Certified, Medical Oncology,  American Board of Internal Medicine

The American Society of Clinical Oncology